naltrexone has been researched along with levodopa in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.52) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ceresoli, G; Groppetti, A; Mandelli, V; Parenti, M | 1 |
| Malone, MH; Namba, MM; Quock, RM | 2 |
| Ané, M; Blin, O; Fabre, N; Montastruc, JL; Poulik, J; Rascol, A; Rascol, O; Sabatini, U; Senard, JM | 1 |
| Flumerfelt, BA; Newman, DD; Rajakumar, N; Stoessl, AJ | 1 |
| Inoue, H | 1 |
| Hobart, J; Katzenschlager, R; Lees, AJ; Manson, AJ | 1 |
| Brotchie, JM; Crossman, AR; Fox, SH; Henry, B | 1 |
| Bédard, PJ; Grégoire, L; Samadi, P | 1 |
| Bédard, PJ; Di Paolo, T; Grégoire, L; Hadj Tahar, A; Rouillard, C; Samadi, P | 1 |
| Benabid, AL; Berger, F; Buggia, V; Gilbert, F; Lévesque, D; Sgambato-Faure, V | 1 |
| Di Paolo, T; Grégoire, L; Lévesque, D; Morissette, M; Ouattara, B; Rouillard, C; Samadi, P; Tamim, MK | 1 |
| Brotchie, JM; DeHaven, RN; DeHaven-Hudkins, DL; Dolle, RE; Fox, SH; Goodman, A; Johnston, TH; Koprich, JB; Le Bourdonnec, B; Little, PJ | 1 |
| Grabowski, J; Green, CE; Lindsay, JA; Moeller, FG; Rathnayaka, NS; Schmitz, JM; Stotts, AL | 1 |
2 trial(s) available for naltrexone and levodopa
| Article | Year |
|---|---|
Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Topics: Aged; Bromocriptine; Cross-Over Studies; Disability Evaluation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Motor Skills; Naltrexone; Neurologic Examination; Parkinson Disease | 1994 |
A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone.
Topics: Adolescent; Adult; Benzhydryl Compounds; Carbidopa; Central Nervous System Stimulants; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Data Interpretation, Statistical; Diagnostic and Statistical Manual of Mental Disorders; Dopamine Agents; Female; Humans; Levodopa; Male; Middle Aged; Modafinil; Motivational Interviewing; Naltrexone; Narcotic Antagonists; Neuropsychological Tests; Patient Compliance; Secondary Prevention; Treatment Outcome; Young Adult | 2014 |
19 other study(ies) available for naltrexone and levodopa
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Corpus Striatum; Drug Interactions; Hydroxydopamines; Levodopa; Male; Morphine; Naltrexone; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Opioid | 1990 |
Narcotic antagonist potentiation of L-DOPA in the reversal of reserpine induced catalepsy.
Topics: Animals; Catalepsy; Drug Synergism; Humans; Levodopa; Male; Mice; Naloxone; Naltrexone; Narcotic Antagonists; Reserpine; Time Factors | 1980 |
Effects of narcotic antagonists on L-dopa reversal of reserpine-induced catalepsy and blepharoptosis in mice.
Topics: Animals; Blepharoptosis; Catalepsy; Drug Antagonism; Drug Synergism; Humans; Kinetics; Levodopa; Male; Mice; Naloxone; Naltrexone; Reserpine | 1981 |
A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease.
Topics: Animals; Apomorphine; Functional Laterality; Hippocampus; Infusions, Parenteral; Levodopa; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Rotation | 1997 |
Effects of naltrexone on the accumulation of L-3, 4-dihydroxyphenylalanine and 5-hydroxy-L-tryptophan and on the firing rate induced by acute ethanol administration.
Topics: 5-Hydroxytryptophan; Animals; Corpus Striatum; Dose-Response Relationship, Drug; Ethanol; Levodopa; Male; Naltrexone; Narcotic Antagonists; Nucleus Accumbens; Rats; Rats, Sprague-Dawley | 2000 |
High dose naltrexone for dyskinesias induced by levodopa.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Naltrexone; Reproducibility of Results | 2001 |
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Therapy, Combination; Dyskinesias; Female; Hypokinesia; Levodopa; Male; Morphinans; Motor Activity; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Posture; Receptors, Opioid, delta; Receptors, Opioid, mu | 2001 |
Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Dopamine; Dopamine Agents; Dopamine Agonists; Dyskinesia, Drug-Induced; Endorphins; Female; Levodopa; Macaca fascicularis; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2; Synaptic Transmission | 2003 |
Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dyskinesias; Female; Levodopa; Macaca fascicularis; Motor Activity; Naltrexone; Narcotic Antagonists; Ovariectomy; Parkinsonian Disorders; Statistics, Nonparametric; Time Factors | 2005 |
Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic Agents; AIDS-Related Complex; Amphetamine; Analgesics, Non-Narcotic; Animals; Antiparkinson Agents; Behavior, Animal; Carrier Proteins; Central Nervous System Stimulants; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dynorphins; Dyskinesia, Drug-Induced; Functional Laterality; Homer Scaffolding Proteins; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Motor Activity; Naloxone; Naltrexone; Narcotic Antagonists; Neurons; Oxidopamine; Protein Precursors; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Stereotyped Behavior; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation | 2005 |
Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cocaine; Corpus Striatum; Disease Models, Animal; Docosahexaenoic Acids; Dopamine; Dopamine Uptake Inhibitors; Dynorphins; Dyskinesia, Drug-Induced; Enkephalins; Female; Iodine Isotopes; Levodopa; Macaca fascicularis; Naltrexone; Neuropeptides; Ovariectomy; Parkinsonian Disorders; Piperidines; Protein Precursors; RNA, Messenger; Sulfonamides; Tachykinins; Thiazoles; Time Factors | 2010 |
The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Macaca fascicularis; Male; Naltrexone; Narcotic Antagonists; Parkinsonian Disorders; Receptors, Opioid, mu | 2011 |